Felix Braberg

Only off by a day, excited to read the results! #avct

@tom_the_bomb__ Fair - just getting jitters that they push it out to next year.

@BrabergFelix They have the data & they've been able to plan for this moment since Q1. The longer they wait the less impact they'll have. A lot of people wind done w/c 15th Dec, so tomorrow or next week for me.

RNS's most likely date, if it happens this year, would be December 16th. This date would leverage post-ASH buzz while giving ample trading days before holidays. #avct

@tom_the_bomb__ I hope you're right

@BrabergFelix Tomorrow or Thurs or Tues-Thurs next week, latest. W/C 15th onwards is no good (IMO).

@CraigBlyth6 lol like reading my own trading history

After 62 months, 42 purchases (including at 257p), I am finally in profit. Long and strong. Patience #AVCT

@SeanDentBsc Hey Sean - I share your frustration. But bottom line is that AVCT despite the science can still fail. The convertible bond payment guarantees the SP to be low as any holders will be diluted further. I’m quite heavily invested in AVCT and still wouldn’t buy more now.

This has to be some kind of parody. UBS believes AZ is undervalued because there is 13bn in sales that have a 57% chance of success. Meanwhile, #AVCT are sat on AT LEAST one drug which has over 90% chance of success, dare I say it almost 100%, that is expected to generate sales of over £2Bn pa and the market cap is just over £100m Crazy disconnect proactiveinvestors.co.uk/companies/news…

@romerley @MylesMcNulty @avacta Great news for share holders and patients!

@MylesMcNulty @avacta It’s not been easy with the trolls, the share price & the shorters! But a core group of people have always put a case forward to believe in the science & although transformative trials are a risk, the benefit gained could be far greater! What an RNS #AVCT

This is possibly the most consequential RNS that @avacta #AVCT has ever put out. "Our first program, AVA6000, demonstrates a four- to six-fold increase in the therapeutic index in the clinic and in preclinical models.... We are now seeing a 75-fold increase in therapeutic index with our recently announced exatecan program, AVA6103 in preclinical models, suggesting that AVA6103 could have an unprecedented safety profile in the clinic." - the maximum tolerated dose of pre|CISION exatecan (AVA6103) observed is 75 times that of conventional exatecan in a daily dosing regimen; - up to 50-fold higher warhead concentrations in the tumor versus plasma in a patient-derived xenograft model; - AVA6103 inhibits tumor growth, with complete responses noted in a preclinical treated model (N.B. multiple CRs!). This drug will obliterate the existing competition in the ADC space (notably, the currently market-leading Enhurtu and Trodelvy ADCs that use Top-1 inhibitors). And I don't mean just surpass; but properly obliterate. The company has nailed the science and the platform now. It can be used to harness immensely toxic warheads - the most potent in existence; and can be used to target as much as three quarters of all cancer cases worldwide. A truly transformational development in the field of oncology. The UK market may not see it immediately (especially given immediate-term Budget concerns and silly games over the HCI bond), but the world of Big Pharma will. I am convinced that Avacta will be acquired within 12 months now - possibly much sooner.

@TatenhillTrader lol I hold Avacta and I even thought that was a bit much- glad to see a more active ceo though

Some absolute dross being posted about #AVCT last night just because the CEO posted a picture and a few words. This ‘cryptic’ message apparently means a TO or 07:00 RNS. Do me a favour!

@conradcarter66 All aboard the rocket ship

@BrabergFelix Don’t be confused, just follow the price action. If it closes above 67p. It’s then 87p and the 200 dma. Imho.

#AVCT, lovely price action. Looks like the gap will be filled up to 67p. Excellent.

@ppphyl @matejlancaric :) Enjoy!

Sunday morning lessons on merge. Mrs Kim seemed to approve 🐱 ✅ Kudos to the 2.5 Gamers podcast by @matejlancaric @BrabergFelix, Jakub Remiar, Laura Taranto for a great deep dive.

@tom_the_bomb__ @avacta Tech looks to work just fine but the leadership lack any commercial acumen… the house then the 95p placing turn down in 2022 just screams amateur..

There will be a *huge* transfer of shares tomorrow. *Who are the buyers is what we should now be asking after this murky raise* Possibly highest volume day. I won’t let anyone have mine. The value is in the IP. That works. #AVCT @avacta

Ignorance is very expensive.

@Jason please have @Carson_C_Block from @muddywatersre on @TWiStartups to talk about Chinese listed unicorns. Would love to hear that discussion!

@Ryanair Is flight 8545 canceled today? Google says yes but your site says no? Can you clarify, please?

@chefmatthews88 I love the work you’re doing! Would you ever consider hosting some meals with @eat_about? PM me for more details.

The @santanderuk Univ. Entrepreneurship Awards are tomorrow! Pitching w/ @Farm_Urban @poweralifeuk @TuringLab @UniGreenScheme! Wish us luck!

Extremely excited to be on tonights Enterprise Connect panel @KingsCollegeLon with @hestonblumentha @JoMaloneMBE @thebodycoach @eat_about

@lavendellady @eat_about It was great to host you all! Hope to see you soon again!

Nevermind holding this under 🔐 Here's how we grow our user base by 16% each week 💪 bit.ly/1NxqlvV #startups #growthhack